Patents by Inventor Raymond J. Winquist

Raymond J. Winquist has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Immunomodulatory IL-2 agents in combination with immune checkpoint inhibitors
    Patent number: 11945870
    Abstract: The invention provides compositions and methods of treating cancer in a patient with a combination therapy comprising a fusion protein of SEQ ID NO: 1 in combination with an immune checkpoint inhibitor. Preferably the patient has failed to achieve complete or partial response with prior or ongoing treatment with an immune checkpoint inhibitor.
    Type: Grant
    Filed: January 4, 2022
    Date of Patent: April 2, 2024
    Assignee: Mural Oncology, Inc.
    Inventors: Heather C. Losey, Jared Lopes, Raymond J. Winquist
  • Immunostimulatory agents in combination with angiogenesis inhibitors
    Patent number: 11834483
    Abstract: The invention provides compositions and methods of treating cancer in a patient with a combination therapy comprising administering to the patient a fusion protein of SEQ ID NO: 1, in combination with an angiogenesis inhibitor (e.g., an anti-VEGF antibody or lenvatinib).
    Type: Grant
    Filed: April 15, 2021
    Date of Patent: December 5, 2023
    Assignee: ALKERMES PHARMA IRELAND LIMITED
    Inventors: Jared Lopes, Heather C. Losey, Raymond J. Winquist
  • COMPOSITIONS AND METHODS FOR SUBCUTANEOUS ADMINISTRATION OF CANCER IMMUNOTHERAPY
    Publication number: 20220241370
    Abstract: The invention provides compositions, methods and treatment regimens for treating cancer comprising periodic subcutaneous administration of the fusion protein of SEQ ID NO:1 to a cancer patient resulting in enhanced activation of CD8+ T-cells with minimal effects on regulatory T cell (Treg) expansion and providing enhanced anti-tumor efficacy while also mitigating T cell inactivation/exhaustion.
    Type: Application
    Filed: January 4, 2022
    Publication date: August 4, 2022
    Inventors: Heather C. Losey, Jared Lopes, Lei Sun, Raymond J. Winquist
  • IMMUNOMODULATORY IL-2 AGENTS IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS
    Publication number: 20220227868
    Abstract: The invention provides compositions and methods of treating cancer in a patient with a combination therapy comprising a fusion protein of SEQ ID NO: 1 in combination with an immune checkpoint inhibitor. Preferably the patient has failed to achieve complete or partial response with prior or ongoing treatment with an immune checkpoint inhibitor.
    Type: Application
    Filed: January 4, 2022
    Publication date: July 21, 2022
    Inventors: Heather C. Losey, Jared Lopes, Raymond J. Winquist
  • Compositions and methods for subcutaneous administration of cancer immunotherapy
    Patent number: 11246906
    Abstract: The invention provides compositions, methods and treatment regimens for treating cancer comprising periodic subcutaneous administration of the fusion protein of SEQ ID NO:1 to a cancer patient resulting in enhanced activation of CD8+ T-cells with minimal effects on regulatory T cell (Treg) expansion and providing enhanced anti-tumor efficacy while also mitigating T cell inactivation/exhaustion.
    Type: Grant
    Filed: June 10, 2020
    Date of Patent: February 15, 2022
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Heather C. Losey, Jared Lopes, Lei Sun, Raymond J. Winquist
  • Immunomodulatory IL-2 agents in combination with immune checkpoint inhibitors
    Patent number: 11248050
    Abstract: The invention provides compositions and methods of treating cancer in a patient with a combination therapy comprising a fusion protein of SEQ ID NO: 1 in combination with an immune checkpoint inhibitor. Preferably the patient has failed to achieve complete or partial response with prior or ongoing treatment with an immune checkpoint inhibitor.
    Type: Grant
    Filed: October 16, 2020
    Date of Patent: February 15, 2022
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Heather C. Losey, Jared Lopes, Raymond J. Winquist
  • IMMUNOSTIMULATORY AGENTS IN COMBINATION WITH ANGIOGENESIS INHIBITORS
    Publication number: 20210347837
    Abstract: The invention provides compositions and methods of treating cancer in a patient with a combination therapy comprising administering to the patient a fusion protein of SEQ ID NO: 1, in combination with an angiogenesis inhibitor (e.g., an anti-VEGF antibody or lenvatinib).
    Type: Application
    Filed: April 15, 2021
    Publication date: November 11, 2021
    Inventors: Jared Lopes, Heather C. Losey, Raymond J. Winquist
  • IMMUNOSTIMULATORY AGENTS IN COMBINATION WITH ANGIOGENESIS INHIBITORS
    Publication number: 20210338656
    Abstract: The invention provides compositions and methods of treating cancer in a patient with a combination therapy comprising administering to the patient a fusion protein of SEQ ID NO: 1, in combination with an angiogenesis inhibitor.
    Type: Application
    Filed: April 15, 2021
    Publication date: November 4, 2021
    Inventors: Jared Lopes, Heather C. Losey, Raymond J. Winquist, Rachel Dusek, Andrew David Simmons
  • IMMUNOMODULATORY IL-2 AGENTS IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS
    Publication number: 20210163596
    Abstract: The invention provides compositions and methods of treating cancer in a patient with a combination therapy comprising a fusion protein of SEQ ID NO: 1 in combination with an immune checkpoint inhibitor. Preferably the patient has failed to achieve complete or partial response with prior or ongoing treatment with an immune checkpoint inhibitor.
    Type: Application
    Filed: October 16, 2020
    Publication date: June 3, 2021
    Inventors: Heather C. Losey, Jared Lopes, Raymond J. Winquist
  • COMPOSITIONS AND METHODS FOR SUBCUTANEOUS ADMINISTRATION OF CANCER IMMUNOTHERAPY
    Publication number: 20210052694
    Abstract: The invention provides compositions, methods and treatment regimens for treating cancer comprising periodic subcutaneous administration of the fusion protein of SEQ ID NO:1 to a cancer patient resulting in enhanced activation of CD8+ T-cells with minimal effects on regulatory T cell (Treg) expansion and providing enhanced anti-tumor efficacy while also mitigating T cell inactivation/exhaustion.
    Type: Application
    Filed: June 10, 2020
    Publication date: February 25, 2021
    Inventors: Heather C. Losey, Jared Lopes, Lei Sun, Raymond J. Winquist